Drug intelligence / Profile preview

QMS-2001

Development stage: Preclinical
Lead developer: Quantumark Science
Modality: Small Molecules

Overview

QMS-2001 is a small-molecule drug candidate currently under development by Quantumark Science for the treatment of cancer. It is designed to function as an immune modulator, aiming to enhance or regulate the body's immune response against malignant cells. While the specific molecular targets of QMS-2001 have not been publicly disclosed by the company, the program represents a core part of Quantumark's oncology pipeline, focusing on the therapeutic potential of small molecules in the field of immuno-oncology.

Beyond the preview

Go deeper on QMS-2001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QMS-2001.

Explore the full profile